ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 241

Analysis of 84 Patients with IgG4-Related Disease and Malignancy

Kazunori Yamada1,2, Ichiro Mizushima2, Hideki Nomura3 and Mitsuhiro Kawano2, 1Department of Advanced Research in Community Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, 2Division of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan, 3Department of General Medicine, Kanazawa University Hospital, Kanazawa, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: IgG4 Related Disease and malignancy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Miscellaneous Rheumatic and Inflammatory Diseases - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic inflammatory disease characterized by an elevated serum level of IgG4, infiltration of IgG4-positive cells in affected organs and fibrosis, and is becoming widely recognized. Recently, some reports have described the relationship between IgG4-RD and malignancy. However, patient background factors such as affected organs and ethnicity in these reports were different. Furthermore, only a few reports analyzed IgG4-RD patients with malignancy who were treated by rheumatologists. This prompted us to analyze the clinical features of IgG4-RD patients with malignancy.

Methods:  Between November 2004 and September 2015, we retrospectively evaluated 84 patients with IgG4-RD in our hospital. We analyzed the prevalence of malignancy, relationship between the appearance of malignancy and diagnosis of IgG4-RD, type of cancer, and related factors. We compared mean age, gender, laboratory data, affected organs and therapy between the malignancy and non-malignancy groups. We also analyzed the standardized incidence ratio (SIR) of newly recognized malignancy after the diagnosis of IgG4-RD.

Results:  There were 53 and 31 male and female patients, respectively with a mean age of 64.9 (range 41-81) years. Average observation period was 4.6 years. Mean serum levels of IgG and IgG4 were 2324±1040 mg/dL, 704±644 mg/dL. The mean number of affected organs was 2.8. The affected organs were as follows: salivary glands (53.6%), lacrimal glands (48.8%), lung (36.9%), retroperitoneum/ periaorta (29.8%), kidney (23.8%) and pancreas (21.4%). Twenty-one malignancies developed in 18 of 84 patients (21.4%), before the diagnosis of IgG4-RD in 11 malignancies in 11 patients (mean 4.3 years earlier, range 0.6-14 years), and after 10 malignancies in 9 patients (mean 1.7 years later, range 0-9 years). Colon cancer, prostate cancer and malignant lymphoma (ML) were seen in three patients each, and gastric, lung and renal cancers and in two patients each. ML developed after the onset of IgG4-RD in all patients. Only two patients developed malignancy in the same organ as affected by IgG4-RD. No significant differences were seen in mean age, gender, laboratory data, affected organs and the prevalence of corticosteroid therapy or the mean dose of prednisolone. We analyzed SIR of newly recognized malignancy after the diagnosis of IgG4-RD in 83 patients who were observed for more than one year. We found that SIR within one year of diagnosis of IgG4-RD was 4.62 and that of the total period of observation was 1.92.

Conclusion:  The present study clarified the incidence, timing, type of malignancy in patients with IgG4-RD treated by rheumatologists. Malignancies developed at a high frequency. However, no specific characteristics were identified, making periodic screening for malignancy of particular importance.


Disclosure: K. Yamada, None; I. Mizushima, None; H. Nomura, None; M. Kawano, None.

To cite this abstract in AMA style:

Yamada K, Mizushima I, Nomura H, Kawano M. Analysis of 84 Patients with IgG4-Related Disease and Malignancy [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/analysis-of-84-patients-with-igg4-related-disease-and-malignancy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-84-patients-with-igg4-related-disease-and-malignancy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology